Spago Nanomedical announces outcome of oversubscribed rights issue

NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER ACTIONS IN ACCORDANCE WITH APPLICABLE LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

On October 29, 2025, the board of directors of Spago Nanomedical AB (publ) (“Spago Nanomedical” or “the Company”) resolved on a new issue of shares with preferential rights for existing shareholders in Spago Nanomedical (the “The Rights Issue”), based on the authorization received at the Annual General Meeting on May 14, 2025. The subscription period for the Rights Issue ended on November 21, 2025. The Rights issue has been subscribed to approximately 105.7 percent, and is therefore oversubscribed. Through the Rights Issue, Spago Nanomedical will receive approximately SEK 25 million before issue costs.

"I am very happy for the confidence that existing and new owners have shown in the Company. With secured financing, we continue the further development of the radionuclide therapy Tumorad® and the candidate drug ¹⁷⁷Lu-SN201, where we see good opportunities to create significant value for both patients and shareholders.”, says Mats Hansen, CEO of Spago Nanomedical

The outcome of the rights issue shows that 298,176,835 shares, corresponding to approximately 95.1 percent of the Rights Issue, were subscribed for with subscription rights, and 33,101,387 shares, corresponding to approximately 10.6 percent, were subscribed for without subscription rights. In total, the Rights Issue was subscribed to approximately 105.7 percent. Spago Nanomedical will thus receive approximately SEK 25 million before issue costs, which are estimated to amount to approximately SEK 1 million.

Notification of allocation of shares subscribed for without subscription rights is expected to be distributed to those who have been allocated shares through a settlement around November 25, 2025. Shareholders whose shares are registered with a custodian will receive notification of allocation in accordance with the respective custodians' routines. Subscribed and allocated shares shall be paid for in cash in accordance with the instructions on the settlement note. The allocation of shares subscribed for without subscription rights has been carried out in accordance with the principles set out in the Company's information document published on November 6, 2025.

Shares and share capital

Through the Rights Issue, the share capital will increase by SEK 3,133,765.80, from SEK 3,481,962.06 to SEK 6,615,727.86 through the issue of 313,376,580 shares, which means that the total number of shares increases from 348,196,206 to 661,572,786, corresponding to a dilution effect of approximately 47.4 percent of the share capital and the number of shares.

Trading in BTA and new shares

The last day of trading in paid subscribed shares (“BTA”) on Nasdaq First North Growth Market is around December 9, 2025. The new shares are expected to start trading on Nasdaq First North Growth Market on December 15, 2025.

IMPORTANT INFORMATION

This press release does not constitute and is not part of an offer to sell securities. Copies of this press release are not and may not be distributed, published or sent to the United States, Australia, Hong Kong, Japan, Canada, Switzerland, Singapore, South Africa or New Zealand or within any other jurisdiction where the distribution of this press release would be unlawful or would require registration or other measures. This press release is for informational purposes only and does not constitute a prospectus or other offer for sale or invitation to an offer to purchase any securities in the United States or any other jurisdiction. Securities that may be issued in connection with the transaction referred to in this press release will not be registered under the U. S. Securities Act of 1933, as amended (the "Securities Act"), and will therefore not be offered or sold in the United States.

This press release does not constitute a prospectus pursuant to Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation"). This press release does not contain and does not constitute an invitation or offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Spago Nanomedical in the United States or elsewhere. The invitation to relevant persons to subscribe for shares in Spago Nanomedical will only be made through the information document that Spago Nanomedical has published on the Company's website. The information document includes, among other things, significant risk factors. This press release has not been approved by any regulatory authority and does not constitute a prospectus. Investors should not subscribe for or purchase securities referred to in this press release except on the basis of the information that was contained in the published information document.

The topics discussed in this press release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should", and similar expressions. Forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although Spago Nanomedical believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, unforeseen events, and other important factors that are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, unforeseen events and other important factors may cause actual events to differ materially from the expectations expressed or implied in this press release through such forward-looking statements. The information, opinions, and forward-looking statements contained in this press release are only valid as of the date of this press release and are subject to change without notice.

The Company considers that it conducts activities that are subject to protection under the Screening of Foreign Direct Investments Act (2023:560) (the "FDI Act"). Consequently, an investment in shares in the Rights Issue (other than on the basis of preferential rights) that results in an investor acquiring a shareholding equal to or exceeding a threshold value of 10, 20, 30, 50, 65, or 90 percent or more of the total number of votes in the Company after the completion of the Rights Issue, must be reported to the Swedish Inspectorate for Strategic Products ("ISP") prior to the investment and, if applicable, to the corresponding authority in accordance with legislation in another jurisdiction, and may not be carried out before the ISP and, if applicable, another corresponding authority in another jurisdiction, has taken no action on the report or approved the investment. Each investor should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue for the individual investor. For more information, please visit the ISP website, www.isp.se, or contact the Company.

Spago Nanomedical announces outcome of oversubscribed rights issue

Back